This is an open-label, non-controlled, non-randomized study to investigate the long-lasting
radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate
response to 177Lu-EB-LM3 in patients with advanced metastatic nasopharyngeal carcinoma.
Different groups with doses of 1.11GBq(1.11GBq)(30 mCi) and 2.22GBq(2.22GBq) (60 mCi)of
177Lu-EB-LM3 will be injected intravenously. All patients will undergo
68Ga-DOTA-Octreotide(TATE) PET/CT scans before and after the treatment.
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University